Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 4, 2008, Pages 442-446

  Campbell, Duncan J ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Amino terminal pro BNP (NT proBNP); Atrial fibrillation; B type natriuretic peptide (BNP); Cardiovascular disease; Heart failure; Myocardial infarction; Risk factor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ACUTE CORONARY SYNDROME; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MONITORING; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK REDUCTION; STROKE; VALVULAR HEART DISEASE;

CARDIOVASCULAR DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS;

EID: 40149102236     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04894.x     Document Type: Conference Paper

References (60)

1. Australian Institute of Health Welfare (AIHW) 2004. Heart, Stroke and Vascular Diseases - Australian Facts 2004. AIHW and National Heart Foundation of Australia (Cardiovascular Disease Series no. 22), AIHW Cat. no. CVD 27. Canberra.
2. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004 109 : 1101 7.
3. Ford ES, Ajani UA, Croft JB et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N. Engl. J. Med. 2007 356 : 2388 98.
4. Capewell S, Unal B, Critchley JA, McMurray JJ. Over 20 000 avoidable coronary deaths in England and Wales in 2000: The failure to give effective treatments to many eligible patients. Heart 2006 92 : 521 3.
5. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004 364 : 937 52.
6. Lloyd-Jones DM, Leip EP, Larson MG et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006 113 : 791 8.
7. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003 326 : 1419 23.
8. New Zealand Guidelines Group. The Assessment and Management of Cardiovascular Risk 2003 nzgg.org.nz/guidelines/0035/CVD_Risk_Full.pdf (Accessed 26 Aug 2007).
9. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: Prospective open cohort study. BMJ 2007 335 : 136 41.
10. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The reynolds risk score. JAMA 2007 297 : 611 19.
11. Richards AM. Natriuretic peptides. Update on peptide release, bioactivity, and clinical use. Hypertension 2007 50 : 25 30.
12. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin. Sci. (Lond.) 2005 108 : 23 36.
13. Campbell DJ, Mitchelhill KI, Schlicht SM, Booth RJ. Plasma amino-terminal pro-brain natriuretic peptide: A novel approach to the diagnosis of cardiac dysfunction. J. Card. Fail. 2000 6 : 130 9.
14. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ. 2005 330 : 625.
15. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 2007 49 : 1733 9.
16. Wallén T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997 77 : 264 7.
17. Ueda R, Yokouchi M, Suzuki T, Otomo E, Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am. J. Med. 2003 114 : 266 70.
18. McDonagh TA, Cunningham AD, Morrison CE et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001 86 : 21 6.
19. Olsen MH, Hansen TW, Christensen MK et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur. Heart J. 2007 28 : 1374 81.
20. McKie PM, Rodeheffer RJ, Cataliotti A et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: Biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006 47 : 874 80.
21. Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 2004 350 : 655 63.
22. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004 90 : 297 303.
23. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005 293 : 1609 16.
24. Pedersen F, Raymond I, Kistorp C, Sandgaard N, Jacobsen P, Hildebrandt P. N-terminal pro-brain natriuretic peptide in arterial hypertension: A valuable prognostic marker of cardiovascular events. J. Card. Fail. 2005 11 : S70 5.
25. Olsen MH, Wachtell K, Tuxen C et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: A LIFE study. J. Hypertens. 2004 22 : 1597 604.
26. Campbell DJ, Woodward M, Chalmers JP et al. Prediction of heart failure by amino-terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 2005 45 : 69 74.
27. Campbell DJ, Woodward M, Chalmers JP et al. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein and renin in subjects with cerebrovascular disease. Circulation 2005 112 : 110 16.
28. Campbell DJ, Woodward M, Chalmers JP et al. Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. Arch. Neurol. 2006 63 : 60 5.
29. Campbell DJ, Neal BC, Chalmers JP et al. Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. Eur. J. Cardiovasc. Prev. Rehabil. 2007 14 : 413 18.
30. Blankenberg S, McQueen MJ, Smieja M et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006 114 : 201 8.
31. Heart Protection Study Collaborative Group. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20 536 patients in the MRC/BHF heart protection study. J. Am. Coll. Cardiol. 2007 49 : 311 19.
32. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N. Engl. J. Med. 2005 352 : 666 75.
33. Schnabel R, Rupprecht HJ, Lackner KJ et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: Results from the AtheroGene study. Eur. Heart. J. 2005 26 : 241 9.
34. Schnabel R, Lubos E, Rupprecht HJ et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: Results from the AtheroGene study. J. Am. Coll. Cardiol. 2006 47 : 552 8.
35. Omland T, Sabatine MS, Jablonski KA et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: The PEACE Trial. J. Am. Coll. Cardiol. 2007 50 : 205 14.
36. Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch. Intern. Med. 2006 166 : 2455 60.
37. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007 297 : 169 76.
38. Olsen MH, Wachtell K, Nielsen OW et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: A LIFE substudy. J. Hypertens. 2006 24 : 1531 9.
39. Ndrepepa G, Kastrati A, Braun S et al. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. Am. J. Med. 2006 119 : 355. e1 8.
40. Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 2006 355 : 2631 9.
41. Redfield MM, Jacobsen SJ, Burnett JC Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003 289 : 194 202.
42. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The cardiovascular health study. J. Am. Coll. Cardiol. 2001 37 : 1042 8.
43. Bella JN, Palmieri V, Roman MJ et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: The Strong Heart Study. Circulation 2002 105 : 1928 33.
44. Gottdiener JS, Arnold AM, Aurigemma GP et al. Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J. Am. Coll. Cardiol. 2000 35 : 1628 37.
45. Campbell DJ, Woodward M, Chalmers JP et al. Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. J. Hypertens. 2007 25 : 699 705.
46. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur. Heart. J. 2003 24 : 475 84.
47. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 358 : 1033 41.
48. Kohno M, Horio T, Yokokawa K et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: Changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am. J. Med. 1995 98 : 257 65.
49. Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin. Sci. (Lond.) 2002 103 : 493 9.
50. Dahlof B, Zanchetti A, Diez J et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J. Hypertens. 2002 20 : 1855 64.
51. Anan F, Takahashi N, Ooie T, Hara M, Yoshimatsu H, Saikawa T. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 2004 53 : 777 81.
52. Olsen MH, Wachtell K, Tuxen C et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: A LIFE substudy. J. Hypertens. 2005 23 : 1083 90.
53. Anan F, Takahashi N, Ooie T et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur. J. Clin. Pharmacol. 2005 61 : 353 9.
54. The CAFE Investigators for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 113 : 1213 25.
55. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 366 : 1545 53.
56. Manuel DG, Lim J, Tanuseputro P et al. Revisiting rose: Strategies for reducing coronary heart disease. BMJ 2006 332 : 659 62.
57. Ware JH. The limitations of risk factors as prognostic tools. N. Engl. J. Med. 2006 355 : 2615 17.
58. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007 115 : 928 35.
59. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007 370 : 591 603.
60. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004 109 : 594 600.